TR201909277T4 - Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. - Google Patents

Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. Download PDF

Info

Publication number
TR201909277T4
TR201909277T4 TR2019/09277T TR201909277T TR201909277T4 TR 201909277 T4 TR201909277 T4 TR 201909277T4 TR 2019/09277 T TR2019/09277 T TR 2019/09277T TR 201909277 T TR201909277 T TR 201909277T TR 201909277 T4 TR201909277 T4 TR 201909277T4
Authority
TR
Turkey
Prior art keywords
rasagiline
extended release
release formulations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
TR2019/09277T
Other languages
English (en)
Inventor
Sela Yoram
Livnah Nurit
Lamensdorf Itschak
Madmon Tomer
Original Assignee
Pharma Two B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43896855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201909277(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Two B Ltd filed Critical Pharma Two B Ltd
Publication of TR201909277T4 publication Critical patent/TR201909277T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Mevcut buluş, özellikle oral uygulama için, nörodejeneratif hastalıkların, özellikle Parkinson hastalığının tedavisinde ve sinir sistemi yaralanmaları için yararlı uzun süreli aktif bileşik salınımı için formüle edilmiş çeşitli farmasötik bileşimler sunmaktadır. Bu bileşimler içinde oluşan aktif bileşik, tercihen N-propargil-1-aminoindan, bunun bir enantiyomeri veya bunun farmasötik olarak kabul edilebilir bir tuzu, daha fazla tercihen rasajilin veya bunun farmasötik olarak kabul edilebilir bir tuzu arasından seçilmektedir.
TR2019/09277T 2010-02-03 2011-02-03 Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. TR201909277T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30101910P 2010-02-03 2010-02-03

Publications (1)

Publication Number Publication Date
TR201909277T4 true TR201909277T4 (tr) 2019-07-22

Family

ID=43896855

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09277T TR201909277T4 (tr) 2010-02-03 2011-02-03 Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.

Country Status (25)

Country Link
US (1) US9943489B2 (tr)
EP (2) EP3517103A1 (tr)
JP (3) JP6045347B2 (tr)
KR (1) KR101791715B1 (tr)
CN (1) CN102791258B (tr)
AU (1) AU2011212068B2 (tr)
BR (1) BR112012019374B1 (tr)
CA (1) CA2789006C (tr)
CL (1) CL2012002175A1 (tr)
CY (1) CY1121781T1 (tr)
DK (1) DK2531181T3 (tr)
ES (1) ES2733133T3 (tr)
HU (1) HUE044221T2 (tr)
IL (1) IL221274A (tr)
LT (1) LT2531181T (tr)
MX (1) MX354423B (tr)
NZ (1) NZ602111A (tr)
PL (1) PL2531181T3 (tr)
PT (1) PT2531181T (tr)
RS (1) RS58988B1 (tr)
RU (2) RU2734632C2 (tr)
SG (1) SG183150A1 (tr)
TR (1) TR201909277T4 (tr)
WO (1) WO2011095973A1 (tr)
ZA (1) ZA201206462B (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2734632C2 (ru) * 2010-02-03 2020-10-21 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
CA2758556A1 (en) * 2011-11-17 2013-05-17 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts
PL2802319T3 (pl) * 2012-01-12 2018-04-30 Pharma Two B Ltd. Leczenie choroby Parkinsona preparatem złożonym
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
CN104220064B (zh) 2012-03-23 2017-10-10 中国人民解放军军事医学科学院毒物药物研究所 一种含辛弗林和托吡酯的联合产品
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
MX2015002062A (es) 2012-08-17 2015-06-05 Teva Pharma Formulaciones parenterales de rasagilina.
WO2014192022A1 (en) * 2013-05-20 2014-12-04 Cadila Healthcare Limited Pharmaceutical compositions of rasagiline
US20150275167A1 (en) * 2014-03-28 2015-10-01 Corning Incorporated Composition and method for cell culture sustained release
RU2745292C2 (ru) 2014-09-15 2021-03-23 Орпхазиме А/C Состав с аримокломолом
CN115715769B (zh) 2017-05-19 2024-10-11 比斯坎神经治疗公司 石杉碱的改良释放药物组合物以及其使用方法
CN107049985B (zh) * 2017-06-07 2020-06-19 广州帝奇医药技术有限公司 一种抗帕金森病药物的长效缓释制剂及其制备方法
BR112021024194A2 (pt) * 2019-05-31 2022-01-11 Denali Therapeutics Inc Formulação de liberação modificada de um composto de pirimidinilamino-pirazol e métodos de tratamento
KR20210014289A (ko) 2019-07-30 2021-02-09 (주)비씨월드제약 라사길린을 함유하는 서방출성 미립구의 제조방법
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
CA3216586A1 (en) * 2021-05-11 2022-11-17 Caroline Roussel-Maupetit Prolonged-release pharmaceutical composition for oral administration of sultiame
CN118680910B (zh) * 2024-08-26 2024-12-03 山东齐都药业有限公司 用于缓释递送雷沙吉兰甲磺酸盐的药物组合物及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5151449A (en) 1990-08-31 1992-09-29 Deprenyl Animal Health, Inc. Use of L-deprenyl for retention of specific physiological functions
US5225446A (en) 1990-08-31 1993-07-06 Deprenyl Animal Health, Inc. Use of 1-deprenyl for retention of specific physiological functions
US5192808A (en) 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
CA2039194C (en) 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
EP0578687A1 (en) 1991-04-04 1994-01-19 The University Of Toronto Innovations Foundation Use of deprenyl to maintain, prevent loss, or recover nerve cell function
AU1992592A (en) 1991-05-24 1993-01-08 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
US5242950A (en) 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
PT966435E (pt) 1996-12-18 2005-06-30 Yissum Res Dev Co Derivados aminoindano
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
US5840979A (en) 1997-07-14 1998-11-24 University Of Saskatchewan Aliphatic propargylamines as cellular rescue agents
PL353180A1 (en) 1999-04-29 2003-11-03 Merck Patent Gmbh Glycine cleavage system inhibitors as potential antipsychotics
EP1411901B1 (en) * 2001-07-04 2010-08-18 Sun Pharma Advanced Research Company Ltd Gastric retention controlled drug delivery system
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
ES2588780T3 (es) * 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
WO2007000779A2 (en) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
CA2616845A1 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
KR20080041669A (ko) * 2005-07-28 2008-05-13 샤이어 엘엘씨 매일 단일 투여량 형태로 투여하기에 적합한 구안파신의약학적 제형물/조성물
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101486655A (zh) 2008-01-17 2009-07-22 美德（江西）生物科技有限公司 甲磺酸雷沙吉兰晶形及其制备方法
PL2303330T5 (pl) 2008-06-06 2021-10-25 Pharma Two B Ltd. Kompozycje farmaceutyczne do leczenia choroby Parkinsona
WO2009151594A1 (en) 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
AR074637A1 (es) * 2008-07-18 2011-02-02 Medichem Sa Formas de sal de adicion acida de r-(+)-n-propargil-1-aminoindano (es decir , base de rasagilina), un compuesto de formula (1), procesos para prepararlos y aislarlos y usos de los mismos
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
RU2734632C2 (ru) * 2010-02-03 2020-10-21 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение

Also Published As

Publication number Publication date
US9943489B2 (en) 2018-04-17
CN102791258A (zh) 2012-11-21
ZA201206462B (en) 2014-02-26
EP2531181A1 (en) 2012-12-12
BR112012019374A2 (pt) 2016-05-03
RU2016141314A3 (tr) 2019-12-20
JP2017031189A (ja) 2017-02-09
JP6440662B2 (ja) 2018-12-19
AU2011212068B2 (en) 2016-08-18
EP2531181B1 (en) 2019-04-10
KR20120130292A (ko) 2012-11-30
RU2012136723A (ru) 2014-03-10
CN102791258B (zh) 2018-05-08
PT2531181T (pt) 2019-07-17
MX2012009079A (es) 2012-12-17
SG183150A1 (en) 2012-09-27
US20120301542A1 (en) 2012-11-29
NZ602111A (en) 2014-10-31
RU2016141314A (ru) 2018-12-14
JP2019048855A (ja) 2019-03-28
IL221274A0 (en) 2012-10-31
HUE044221T2 (hu) 2019-10-28
ES2733133T3 (es) 2019-11-27
BR112012019374B1 (pt) 2022-01-11
JP6045347B2 (ja) 2016-12-14
AU2011212068A1 (en) 2012-09-20
CY1121781T1 (el) 2020-07-31
IL221274A (en) 2017-05-29
JP6770564B2 (ja) 2020-10-14
RU2607595C2 (ru) 2017-01-10
LT2531181T (lt) 2019-07-10
KR101791715B1 (ko) 2017-10-30
RU2734632C2 (ru) 2020-10-21
PL2531181T3 (pl) 2019-09-30
RS58988B1 (sr) 2019-08-30
CA2789006C (en) 2018-11-27
CA2789006A1 (en) 2011-08-11
CL2012002175A1 (es) 2013-01-11
JP2013518870A (ja) 2013-05-23
WO2011095973A1 (en) 2011-08-11
MX354423B (es) 2018-03-02
DK2531181T3 (da) 2019-07-15
EP3517103A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
ZA202202711B (en) Sustained-release dosage forms of ruxolitinib
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
MY165149A (en) Use of binders for manufacturing storage stable formulations
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
NZ605469A (en) Nalbuphine-based formulations and uses thereof
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2015001917A (es) Composiciones farmaceuticas de memantina.
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
PH12015500823A1 (en) Modified release formulations for oprozomib
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
UA117154C2 (uk) Антагоністи s1p3
MX2012012410A (es) Agente terapeutico y agente preventivo para enfermedad de alzheimer.
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
EA201390619A1 (ru) 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения
PH12019501070A1 (en) Sustained-release dosage forms of ruxolitinib
MX2008011017A (es) Compuestos de receptor sigma.
UA101370C2 (ru) Пероральные составы, которые содержат аналоги цитидина, и способы их использования
TH138424A (th) สูตรผสมผงแห้งที่ประกอบรวมด้วยยาต้านมัสคารินิก